Espoo, Finland, May 15th, 2024. Euformatics, a world leader in NGS quality control and variant interpretation tools, announced that it has signed a new commercial partnership with Ouilab Group in France. As part of the collaboration, Euformatics delivers the full Genomics Hub software suite to laboratories in Strasbourg and Laxou to power their clinical genomics data analysis workflows.
Ouilab Group is a first national independent provider of diagnostic laboratory services in France composed of 5 companies, 17 technical platform and 160 sampling sites. Each member laboratory in the group makes their decisions independently to best serve needs of their customers and patients. Recent introductions of new innovation in high quality NGS sequencing provided an opportunity to optimize the workflow from wet lab to clinical report by combining Element Bioscience’s AVITI sequencer and Euformatics Genomics Hub.
Vincent Lehmann, Managing Director at Ouilab, comments: “We explored the output of Element Bio AVITI together with the Euformatics team and concluded that the instrument and software combination is most suitable for our needs. We emphasize the importance of maintaining intellectual control of the entire analytical process in order to develop our skills and expertise. We have multiple options to adapt Euformatics’ tools to our specific needs and the support that we are getting for developing and validating workflows is important when moving to clinical production.”
Charlotte Felici, Medical Biologist at Ouilab Laxou laboratory, continues: “From a biologist perspective Euformatics provides tools for deep exploration into the genomic profile of the patient. The tools also allow paying particular attention to controlling the life cycle of the wet lab, sequencing, and bioinformatics processes through rigorous validation and regular QC. Christophe’s team at Euformatics provides very good support in setting up our pipelines, parameters, and quality thresholds for the clinical workflow; and all of it in French.”
Euformatics’ Chief Scientific Officer, Christophe Roos concludes: “I have enjoyed working with Ouilab on a practical level. They have a high level of expertise and ambition, both of which are needed for test development in the demanding domain of clinical molecular genetics. Setting up and validating a new instrument platform as well as trimming the variant analytics strategies needs to be done carefully, considering the whole workflow from wet lab to clinical report. This is an area where we have worked closely together with the Strasbourg and Laxou labs.”
About Euformatics:
Euformatics is a Finnish software company that specializes in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the Genomics Hub which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.
For more information, visit www.euformatics.com
About Ouilab Group:
Founded in 2019 out of the desire to create an independent and strong regional entity, the OuiLab Group was born from the merger of 3 historic players in the Grand Est, the EspaceBio, Bio67 and BioAllan laboratories. In 2021, the Dynalab laboratories will join the group and in 2022 the Central 92 laboratories and Biosmose. It was in the midst of the Covid-19 health crisis that biologists united, resolutely motivated to take on the new challenges of their professions together. Driven by common values, they have chosen to combine their skills and pool their know-how. True specialists in medical biology, Ouilab invests in a wide range of specialties.
For more information visit www.ouilab.com
Press Relations:
Tommi Kaasalainen
Euformatics
tommi.kaasalainen@euformatics.com
